EB 003 - Enveric Biosciences
Alternative Names: EB-003 - Enveric BiosciencesLatest Information Update: 05 Jan 2026
At a glance
- Originator Enveric Biosciences
- Class Antidepressants; Anxiolytics; Small molecules
- Mechanism of Action Serotonin 1B receptor agonists; Serotonin 5-HT2A receptor agonists
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Anxiety disorders; Depressive disorders
Most Recent Events
- 29 Dec 2025 Enveric Biosciences receives patent allowance for Substituted Ethylamine Fused Heterocyclic Mescaline Derivatives in the US
- 16 Sep 2025 Enveric Biosciences receives written response from the US FDA to its request for a pre-IND Type B meeting for EB 003
- 02 Sep 2025 Enveric Biosciences plans a phase-I clinical trial for Depressive disorders and Anxiety disorders in 2026